leisure time -WSS

leisure time

author：explore 2025-09-29 01:36:47 - browse：94

A black and white cutout photo of Feng Zhang on the left of a black and white cutout photo of Alex Aravanis. Both photos are placed on top of yellow geometric shapes and a gradient dark blue background. — Researcher Feng Zhang, left, and Alex Aravanis, the CEO of Moonwalk. Illustration: Christine Kao/STAT; Photo: Katherine Taylor for STAT and Business Wire

A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand.

Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. It plans to use that money to develop treatments for a variety of diseases, including chronic and aging-related conditions, using what’s called epigenetic editing.

Most of the gene editing technologies being used today slice or nick the DNA strand and make permanent changes to the biological building blocks of genes. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes. The company is targeting the surrounding chemicals that influence how genes act. This can be done through chemical processes methylation, which turns genes on, or demethylation, which turns genes off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： WuXi Biologics beefs up its lobbying operation

WSS

The United States must get value

Xenotransplantation trials will require adjusting expectations, experts say

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

The United States must get value

What a koala virus tells us about the human genome

focus

leisure time

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Xenotransplantation trials will require adjusting expectations, experts say

Anesthesiologist group: stop taking Ozempic before surgery

STAT reporters are Pulitzer Prize finalists for investigative reporting

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The United States must get value

Psychedelics group wrestles with new pharma identity

Altering the blood type of lungs raises potential for universal organs for transplants

DIEP, the 'gold standard' of breast reconstruction, is under threat

Galapagos to make CAR

hotspot

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Novo Nordisk testing Wegovy against alcohol

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

The thinking behind the controversial eating disorder chatbot Tessa

Lilly’s weekly insulin works as well as daily products, new studies show

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

leisure time

leisure time

explore

Wikipedia